These results, together with our recently reported findings demonstrating that lack of combined immunoreactivity for FGFR2 and activated RSK (RSK-P) was predictive of a better patients’ DFS [30] suggest that FGF7/FGFR2 induces degradation and activity of PR which may contribute to microenvironment-driven shift of breast cancer cells towards hormone independence. Here, FGFR2 is linked to breast cancer.